290 related articles for article (PubMed ID: 27567888)
1. Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2016 Oct; 5(3):285-296. PubMed ID: 27567888
[TBL] [Abstract][Full Text] [Related]
2. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
3. 'Super-Enrichment' Reveals Dose-Dependent Therapeutic Effects of Environmental Stimulation in a Transgenic Mouse Model of Huntington's Disease.
Mazarakis NK; Mo C; Renoir T; van Dellen A; Deacon R; Blakemore C; Hannan AJ
J Huntingtons Dis; 2014; 3(3):299-309. PubMed ID: 25300333
[TBL] [Abstract][Full Text] [Related]
4. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
5. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.
van Dellen A; Cordery PM; Spires TL; Blakemore C; Hannan AJ
BMC Neurosci; 2008 Apr; 9():34. PubMed ID: 18380890
[TBL] [Abstract][Full Text] [Related]
6. Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.
Herbst EA; Holloway GP
Neuroscience; 2015 Sep; 303():515-23. PubMed ID: 26186895
[TBL] [Abstract][Full Text] [Related]
7. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
[TBL] [Abstract][Full Text] [Related]
8. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
9. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy.
Sawiak SJ; Wood NI; Morton AJ
J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335
[TBL] [Abstract][Full Text] [Related]
10. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
[TBL] [Abstract][Full Text] [Related]
11. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.
Wood NI; Glynn D; Morton AJ
Neurobiol Dis; 2011 Jun; 42(3):427-37. PubMed ID: 21324361
[TBL] [Abstract][Full Text] [Related]
12. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease.
El-Akabawy G; Rattray I; Johansson SM; Gale R; Bates G; Modo M
BMC Neurosci; 2012 Aug; 13():97. PubMed ID: 22876937
[TBL] [Abstract][Full Text] [Related]
13. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.
Wood NI; Carta V; Milde S; Skillings EA; McAllister CJ; Ang YL; Duguid A; Wijesuriya N; Afzal SM; Fernandes JX; Leong TW; Morton AJ
PLoS One; 2010 Feb; 5(2):e9077. PubMed ID: 20174443
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.
Fisher SP; Black SW; Schwartz MD; Wilk AJ; Chen TM; Lincoln WU; Liu HW; Kilduff TS; Morairty SR
Brain; 2013 Jul; 136(Pt 7):2159-72. PubMed ID: 23801738
[TBL] [Abstract][Full Text] [Related]
15. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
16. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.
Zajac MS; Pang TY; Wong N; Weinrich B; Leang LS; Craig JM; Saffery R; Hannan AJ
Hippocampus; 2010 May; 20(5):621-36. PubMed ID: 19499586
[TBL] [Abstract][Full Text] [Related]
17. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
Dufour BD; McBride JL
Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
[TBL] [Abstract][Full Text] [Related]
18. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
Mo C; Renoir T; Hannan AJ
Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
[TBL] [Abstract][Full Text] [Related]
20. Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.
Berggren KL; Chen J; Fox J; Miller J; Dodds L; Dugas B; Vargas L; Lothian A; McAllum E; Volitakis I; Roberts B; Bush AI; Fox JH
Redox Biol; 2015; 4():363-74. PubMed ID: 25703232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
